Navigation Links
Therapy exploits 'addiction' of leukemia cells
Date:4/16/2012

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

Many cancers are associated with the loss of function of the PTEN tumor suppressor gene, including T-cell acute lymphoblastic leukemia (T-ALL). Loss of PTEN leads to unbridled activation of the PI3K/Akt signaling pathway that drives tumor growth and survival. "We know that there are multiple types of PI3K molecules, designated PI3K, , , or , the unrestricted activities of which could contribute to these processes," explains senior study author, Dr. Thomas Diacovo, from Columbia University Medical Center. "However, what role, if any, distinct PI3K subtypes play in the pathogenesis of T-ALL was unknown."

Using a mouse model of T-ALL, Dr. Diacovo and colleagues found that in the absence of PTEN, the unrestricted activity of either PI3K or PI3K was sufficient to support cancer progression and that deletion of both subtypes was required to impair the development of T-ALL. "We found that these two molecules act as a kind of bottleneck in the progression of T-ALL and that the cancer cells can become addicted to these two specific signaling molecules," says Dr. Diacovo. The researchers went on to show that dual inhibition of both PI3K subtypes was necessary to prolong survival of mice with T-ALL and to promote the death of human tumor cells.

"Our work represents a significant advancement in the understanding of the dynamic interplay that exists between PTEN and specific PI3K subtypes in regulating both normal and abnormal T cell development, as well as in sustaining tumor proliferation and survival," concludes Dr. Diacovo. "By pinpointing these therapeutic targets, it may be possible to limit the toxicity that is associated with current T-ALL therapies and to avoid the potential global impact that less selective inhibition of the PI3K/Akt signaling pathway may have on cancer patients."


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Immunotherapy for elderly cancer patients finds new promise in drug combination
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
4. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
5. Long-Term Estrogen Therapy Does Up Breast Cancer Risk: Study
6. Progress toward new chemotherapy agents
7. New genomic test spares patients chemotherapy with no adverse effect on survival
8. Radiotherapy for DCIS still protects against recurrence after 15 years
9. Double whammy: RNAi enhances lung cancer therapy
10. Adrenaline Therapy for Cardiac Arrest Linked to Worse Outcomes
11. Stem Cell Therapy Could Boost Kidney Transplant Success: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 26, 2016 ... value-based care operating models within the health care industry ... greater financial efficiency , Deloitte offers a suite ... key business issues impacting efficient cost optimization: labor resource ... , These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
Breaking Medicine Technology: